Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool October 27, 2005 Stephen D. Simpson	What's New With Novo? Novo Nordisk is a good play on diabetes, but will new drugs reduce the need for insulin? Investors, take note.
The Motley Fool April 28, 2005 Stephen D. Simpson	Novo Nordisk Could Use a Boost Investors reacted badly to first-quarter results, but there's still a lot to like about the Danish pharmaceutical.
The Motley Fool January 28, 2005 Stephen D. Simpson	An Understated Scandinavian The Danish pharmaceutical may not be quite cheap enough to be a true value, but investors looking for a solid growth stock should see what's new with Novo Nordisk.
The Motley Fool February 4, 2008 Brian Lawler	Best International Stock: Novo Nordisk A quick summary of Danish drugmaker Novo Nordisk, the world's number one manufacturer of diabetes medications.
The Motley Fool January 27, 2006 Stephen D. Simpson	Challenges Needle Novo Nordisk The insulin franchise is attractive, but under threat. Guidance for 2006 wasn't impressive and there are definite challenges ahead. Investors, take note.
Chemistry World September 24, 2012 Andrew Turley	$100m of diabetes R&D in China Danish drug maker Novo Nordisk has announced plans to invest $100 million in its R&D site in Beijing, China. The move will create 130 -- 200 new research jobs.
The Motley Fool October 31, 2008 Brian Orelli	Disease Is Good for Novo Nordisk The Danish drugmaker is able to grow despite the Danish krone moving against the currencies that predominate its sales..
The Motley Fool October 31, 2006 Brian Lawler	Novo Nordisk Still Knows Sales There's more competition in diabetes care now, but the Danish pharmaceutical is thriving. Investors, take note.
The Motley Fool January 16, 2008 Brian Lawler	Another Inhalable Insulin Bites the Dust Novo Nordisk discontinues development of its troubled diabetes treatment and settles its patent infringement lawsuit against Pfizer. Investors, take note.
Chemistry World November 9, 2010 Andrew Turley	Company snapshot: Novo Nordisk As the results for the third quarter of this year roll in, one pharma major - Danish company Novo Nordisk - seems to have done better than most with its diabetes medicines.
The Motley Fool April 30, 2008 Brian Lawler	A Dominating Danish Drugmaker Novo Nordisk turns in solid first-quarter financial numbers.
The Motley Fool July 19, 2007 Brian Orelli	Head to the U.S. to Sue Your Neighbor Danish Novo Nordisk and French Sanofi-Aventis fight over insulin-delivery systems. Since the patent covers the U.S., the two companies will need to fight it out in U.S. courts.
The Motley Fool August 8, 2008 Brian Lawler	Not Bad, Novo Nordisk The drugmaker's performance is better than its numbers suggest.
Chemistry World June 16, 2014 Phillip Broadwith	Novo Nordisk to create 6000 jobs by 2022 Danish insulin and diabetes specialist Novo Nordisk says it intends to employ 6000 more highly skilled workers within Denmark by 2022. Half of these new staff will work in R&D.
The Motley Fool November 5, 2007 Brian Lawler	Follow the Trend With Novo Nordisk The future is bright for Danish drugmaker Novo Nordisk. The worldwide leader in diabetes treatments turns in another good quarter.
The Motley Fool June 24, 2008 Brian Orelli	A Diabetes Drug Delivery Deal Several pharmaceutical companies compete to deliver a diabetes medication that can be taken orally or once-weekly.
The Motley Fool January 31, 2007 Brian Lawler	Novo Nordisk Knows Sales Growth Diabetes care leads the way for this Danish drugmaker. Investors willing to do a little extra financial sleuthing will find a pharmaceutical company that's the global leader in a rapidly growing health-care segment.
Chemistry World September 3, 2014 Phillip Broadwith	Novo Nordisk quits inflammation R&D and cuts jobs Novo Nordisk is terminating its inflammatory disease R&D programs after the company's leading rheumatoid arthritis drug candidate failed in clinical trials.
BusinessWeek April 30, 2010 Drew Armstrong	The Lobbying for Death by Diabetes How a health-reform provision may help spur sales of insulin.
The Motley Fool July 27, 2007 Rich Duprey	Sniffing Out Bentley's New Patent To succeed in insulin therapy, the generic drugmaker must overcome patent expiration. Investors, take note.
The Motley Fool June 27, 2005 Stephen D. Simpson	Sniffing Out a Possible Diabetes Blockbuster Inhaled insulin has been a Holy Grail of diabetes care. Will it live up to lofty expectations? Pfizer, Sanofi-Aventis, and Lilly are all interesting in their own right as high-quality pharmaceutical companies, and more aggressive investors should take a look at Nektar and Alkermes, as well.
The Motley Fool September 30, 2008 Brian Lawler	Novo Nordisk Takes On All Comers Its diabetes franchise is about to get bigger.
The Motley Fool May 20, 2009 Brian Orelli	Joining to Treat, and Beat, Diabetes Medical-device maker Medtronic and drugmaker Eli Lilly are teaming up to co-promote the companies' diabetes products to doctors and patients.
The Motley Fool June 27, 2008 Brian Lawler	This Drug Market Is Booming One therapeutic category seems to be expanding significantly faster than most of its peers, the one that helps the unfortunately burgeoning number of diabetics in the U.S. and worldwide.
The Motley Fool June 13, 2008 Brian Lawler	Novo Nordisk Bleeds a Little The pharmaceutical's hot streak ends as a vital study fizzles out.
The Motley Fool June 29, 2011 Brian Orelli	So Much Insulin, So Little Use for It MannKind settles its supply agreement with Merck.
The Motley Fool August 21, 2007 Brian Orelli	Sweet Phase 3 Data Although diabetes drugs have come under fire lately, insulin maker Novo Nordisk is moving full steam ahead with its newest drug to help fight type 2 diabetes.
American Family Physician July 15, 2006 Jennifer D. Goldman-Levine	Insulin Detemir (Levemir) for Diabetes Mellitus Insulin detemir is suitable as basal insulin in a basal-bolus regimen. In limited research, it has been shown to cause slightly fewer episodes of minor hypoglycemia and no weight gain in patients with type 1 and 2 diabetes, which is a benefit that must be balanced against its higher price.
The Motley Fool July 21, 2005 Stephen D. Simpson	Tiger Lilly or Wilting Daisy? For now, Lilly seems to me to be a middle-of-the-road type of pharmaceutical stock. There are plenty of worse ideas out there, but there are better ideas, as well.
The Motley Fool December 5, 2008 Brian Orelli	Be Kind to MannKind MannKind has good data on its inhaled insulin drug, but will the FDA approve of it and will diabetics buy it?
The Motley Fool October 2, 2009 Brian Orelli	Warning! Potential Blockbuster Ahead It's a little early to call it, but it looks like Bristol-Myers Squibb and AstraZeneca have a potential blockbuster on their hands with their new diabetes drug.
The Motley Fool September 30, 2011 Brian Orelli	A Drug Market That's 366 Million Strong Diabetes drugs have potential.
The Motley Fool June 19, 2009 Robert Steyer	MannKind Needs More Leaps Getting FDA approval for its inhaled-insulin product is only one hurdle for this start-up pharmaceutical.
Pharmaceutical Executive October 1, 2005	Changing Diabetes An interview with Novo Nordisk's president of U.S. operations Martin Soeters on how a nation that leads the world in diabetes research does such a poor job of treating it. Here, he offers some solutions.
Pharmaceutical Executive November 1, 2014 William Looney	Dane in America Jesper Hoiland, Novo Nordisk's President for North America, assesses the challenges and opportunities during his first year at the helm of the diabetes franchise leader's biggest affiliate market.
The Motley Fool October 18, 2010 Brian Orelli	Pfizer Flexes Its Generic Muscles The pharma giant moves farther into generic drugs.
The Motley Fool June 9, 2008 Brian Lawler	Novo Nordisk's Daring Success Novo Nordisk's potential blockbuster compound excels in late-stage head-to-head testing. Investors, take note.
The Motley Fool November 13, 2007 Brian Lawler	Nektar's New Old Drug Pfizer returns its non-selling inhalable insulin experiment Exubera to Nektar Therapeutics today, along with $135 million in cash.
The Motley Fool June 2, 2010 Brian Orelli	Take Your Low Margins and Shove 'Em In an effort to help lower its budget problems, Greece told drugmakers it was slashing prices of drugs, take it or leave it. Novo Nordisk chose "leave it."
American Family Physician November 1, 2000	Diabetes: Flexible Insulin Regimens for People with Type 1 Diabetes What is insulin?... How do I use insulin?... What is a flexible insulin regimen?... When should I take insulin?...
The Motley Fool February 28, 2007 Brian Lawler	No Dice for Novo Novo Nordisk reports a failed clinical trial for one of its top drugs. Shares were down more than 5% on the news.
The Motley Fool October 2, 2007 Brian Orelli	Amylin's Bittersweet FDA News Diabetes drug moves ahead, but not as much as the company wanted. If the FDA rejection was due to safety issues, that wouldn't bode well for Amylin's plans to develop the active ingredient in SYMLIN as a weight-loss drug. Investors, take note.
The Motley Fool July 22, 2009 Brian Orelli	The Blockbuster Around the Corner Amylin Pharmaceuticals' Byetta sales are improving, but is it enough?
The Motley Fool July 30, 2010 Brian Orelli	MannKind: Strengths, Weaknesses, Opportunities, Threats It's all about the inhaled insulin.
The Motley Fool January 26, 2010 Brian Orelli	Is Victoza's Victory in Vain? Novo Nordisk finally gets the FDA to sign off on its once-daily diabetes drug.
American Family Physician May 1, 2001	Treatment Options for Type 2 Diabetes -- What's Available? What are the different steps in managing my diabetes? What are the different types of medicines used to treat type 2 diabetes and how do they work?
The Motley Fool December 3, 2010 Brian Orelli	Merck Smartens Up The acquisition of SmartCells looks like an intelligent move.
The Motley Fool May 22, 2006 Stephen D. Simpson	Nektar Full of Potential, Risk Can inhaled insulin sales live up to investors' expectations at Nektar Therapeutics?
The Motley Fool September 22, 2010 Brian Orelli	Better Buy: Amylin Pharmaceuticals or MannKind? It's a diabetes-drug showdown.
The Motley Fool June 29, 2009 Brian Orelli	Lantus Results: Reply Hazy, Try Again Later Drugmaker Sanofi's problems become murkier. Investors are relieved that the data is out -- Sanofi is up about 4.5% at the moment -- but it seems prudent to be cautious here.